The current test for prostate cancer, which measures blood levels of prostate-specific antigen (PSA), detects 85% of prostate cancer cases but gives a "false positive" (a test result that wrongly indicates the presence of disease) in 80% of cases.

New study: Researchers tested 330 men for elevated levels of early prostate cancer antigen-2 (EPCA-2).

Result: EPCA-2 detected 94% of prostate cancer cases with only a 3% false-positive rate. EPCA-2 testing could be available to the public within two years.

Want to Keep Reading?

Continue reading with a Health Confidential membership.

Sign up now Already have an account? Sign in